Developmental Funds

摘要 从2012年到2017年，乔治敦隆巴迪综合癌症中心（LCCC）分发了131.8万美元的 CCSG发展，以支持试点研究项目（76.1万美元），制药商发起的试验（早期阶段 临床研究支持[EPCRS]）（17.3万美元）和研究计划优先事项（38.4万美元）。其他资金来源 （总额为216.6万美元，包括替代赠款机制、慈善事业和合作伙伴的支持） 机构被用来支持职业发展、专门试点项目、共享资源开发 与LCCC的战略计划相一致。 CCSG为20个研究项目和3个指定团队科学举措提供了760，980美元的支持， 从2012年到2017年，在额外的赠款资金和24篇出版物中产生了757万美元的投资回报率（ROI）。 此外，这些资金（包括2017年14.5万美元的指定支持）使P01的提交成为可能。 拨款重点关注肝癌早期检测、开发胰腺孢子应用以及启动 生存研究工作。 七项早期阶段研究者发起的临床试验（ITT）得到了CCSG资金的172，617美元支持 在目的2下，共累积了106个科目。ROI包括3篇出版物和5篇演讲。 向目标3中的方案提供的资金支持了年度务虚会（所有方案）， 癌症TMA（BC）和试点资金（CPC）。 额外的发展基金支持职业发展研究（ACS IRG），乳腺癌，GI 癌症和免疫治疗研究，并为HTSR购买了Vectastain成像平台， Nextseq 550测序仪用于GESR和Khleif（ET）和Pearson（BC）的招募。 在下一个赠款周期，我们建议继续使用CCSG资金来支持同行评审的试点赠款， 领导指导高优先级的多研究者研究工作，IIT和计划优先事项。额外资金 将有助于进一步巩固我们与JTCC的关系，并支持推进我们的战略所需的招聘 优先事项

ABSTRACT From 2012 to 2017, the Georgetown Lombardi Comprehensive Cancer Center (LCCC) distributed $1.318M of CCSG developmental to support Pilot Research projects ($761K), investigator-initiated trials (Early Phase Clinical Research Support [EPCRS]) ($173K) and Research Program priorities ($384K). Other sources of funds (totaling $2.166M included alternative grant mechanisms, philanthropy and support from collaborating institutions were used to support career development, specialized pilot projects, shared resource development and recruitment largely in concert with LCCC’s strategic plan. CCSG support of $760,980 provided to 20 research projects and 3 designated team science initiatives under from 2012-2017 yielded a Return On Investment (ROI) of $7.57M in additional grant funding and 24 publications. In addition, these funds (including $145K of designated support in 2017) have enabled the submission of a P01 grant focused on liver cancer early detection, a developing Pancreatic SPORE application and the priming of survivorship research efforts. Seven early phase Investigator-initiated clinical trials (ITTs) were supported with $172,617 from CCSG funds under Aim 2, and have accrued a total of 106 subjects. ROI has included 3 publications and 5 presentations. Funds provided to Programs in Aim 3 have supported Annual Retreats (all programs), the creation of Breast Cancer TMA (BC) and pilot funding (CPC). Additional developmental funds have supported career development research (ACS IRG), breast cancer, GI cancer and immunotherapy research and enabled the purchase of a Vectrastain imaging platform for HTSR, a Nextseq 550 sequencer for GESR and the recruitment of Khleif (ET) and Pearson (BC). In the next grant cycle we propose to continue to use CCSG funds to support peer-reviewed pilot grants, leadership directed high priority multi-investigator research efforts, IITs and Program priorities. Additional funds will help further cement our relationship with JTCC and support recruitment needed to advance our strategic priorities.